> For the complete documentation index, see [llms.txt](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology/evidence-summary.md). # Evidence Summary ## Evidence Summary ### Research overview Apigenin has been studied across hundreds of peer-reviewed papers in cell, animal, and human pharmacokinetic settings. The volume of research is large. The clinical translation is still limited. Most evidence comes from cell-line work. These studies repeatedly show inhibition of cancer cell proliferation, induction of apoptosis, cell-cycle arrest, and pathway modulation across a wide range of tumour types. Animal work supports those findings in several settings, especially hepatocellular carcinoma, prostate, colorectal, and lung cancer. A meta-analysis of animal studies found statistically significant reductions in tumour volume and tumour weight, with no significant effect on body weight across multiple cancer types. Human-level evidence is limited to pharmacokinetic studies, one registered absorption and metabolism study (`NCT03526081`), and broader dietary epidemiology on flavonoid intake. No completed randomised clinical trial has tested apigenin against human cancer outcomes. ### Clinical application status Apigenin is not an approved cancer drug. It does not have an established oncology dose, schedule, or treatment protocol. Current clinical relevance is limited to: * understanding pharmacokinetics and what doses are achievable in humans * evaluating the preclinical rationale for adjunctive use alongside conventional treatment, especially in apoptosis-resistance and chemosensitisation settings * investigating advanced delivery systems, including liposomal, nanoparticle, and SNEDDS formulations, to improve exposure ### Key advantages * Targets the anti-apoptotic BCL-2 family, especially `MCL-1` and `BCL-xL`, which are directly linked to therapy resistance * Suppresses multiple survival and resistance pathways at once, including `STAT3`, `NF-κB`, `PI3K/AKT/mTOR`, and `Wnt/β-catenin` * Shows anti-metastatic effects in animal models across melanoma, ovarian, liver, prostate, and colorectal settings * Repeatedly improves chemosensitivity in preclinical models with several conventional drugs * Shows a generally favourable preclinical safety pattern, with no significant toxicity signal at tested animal doses * Adds senomorphic, SASP-suppressing activity that may reduce pro-tumourigenic signalling from senescent stromal cells ### Key considerations * All oncology efficacy data are preclinical * No completed human cancer outcome trials exist * Oral bioavailability is limited, so matching effective preclinical tissue exposure is not straightforward with conventional supplementation * Most combination data are cell-line or animal-based, so real clinical interaction profiles remain undefined * Long-term safety at pharmacological human doses is not established * `CYP2C9` and `CYP3A4` inhibition create real interaction potential with drugs processed through those pathways ### Bottom line The apigenin evidence base is serious and mechanistically coherent. It is not clinical proof. The strongest case rests on repeated findings across BCL-2 family modulation, chemosensitisation, anti-metastatic activity, and SASP suppression. That is enough to justify research attention and careful adjunctive consideration by readers already working at the evidence level. It is not enough to claim proven clinical benefit. ### References * Yan X, et al. [Apigenin in cancer prevention and therapy: A systematic review and meta-analysis](https://www.sciencedirect.com/science/article/abs/pii/S1040842822001755) * Chmielewska M, et al. [Does Oral Apigenin Have Real Potential for a Therapeutic Effect in Cancer?](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.681477/full) * [NCT03526081 — Absorption, Metabolism and Excretion of Apigenin in Humans](https://clinicaltrials.gov/study/NCT03526081) --- # Agent Instructions This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com. ## Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology/evidence-summary.md?ask=&goal= ``` `ask` is the immediate question: it should be specific, self-contained, and written in natural language. `goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.